Abstract: China's biopharmaceutical industry had been accelerating its return to the value essence and focused on improving the innovation quality in 2022. In 2023, biopharmaceutical enterprises should adhere to the clinical value-oriented research and development concept, pay attention to global markets with an international perspective, remain open and deepen innovation collaboration with domestic and foreign enterprises, and foster high-quality innovative drugs.Through multiple rounds of brainstorming roundtables, Shanghai Center for Innovation Drug Discovery and Development (SCIDDD) made the 2023 annual outlook on China's biopharmaceutical industry, and proposed that biopharmaceutical enterprises need to focus on openness, collaboration and quality, to continuously enhance the value of innovative drugs.